Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,917 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.
Wagner H, Lood C, Borna C, Gidlöf O, Truedsson L, Brown P, Zhou C, Winters K, Jakubowski JA, Erlinge D. Wagner H, et al. Among authors: brown p. J Thromb Thrombolysis. 2016 Oct;42(3):369-75. doi: 10.1007/s11239-016-1372-1. J Thromb Thrombolysis. 2016. PMID: 27165280 Clinical Trial.
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.
Wagner H, Angiolillo DJ, Ten Berg JM, Bergmeijer TO, Jakubowski JA, Small DS, Moser BA, Zhou C, Brown P, James S, Winters KJ, Erlinge D. Wagner H, et al. Among authors: brown p. J Thromb Thrombolysis. 2014;38(2):127-36. doi: 10.1007/s11239-013-0987-8. J Thromb Thrombolysis. 2014. PMID: 24043374 Clinical Trial.
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
Erlinge D, Ten Berg J, Foley D, Angiolillo DJ, Wagner H, Brown PB, Zhou C, Luo J, Jakubowski JA, Moser B, Small DS, Bergmeijer T, James S, Winters KJ. Erlinge D, et al. J Am Coll Cardiol. 2012 Nov 13;60(20):2032-40. doi: 10.1016/j.jacc.2012.08.964. Epub 2012 Oct 17. J Am Coll Cardiol. 2012. PMID: 23083774 Free article.
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
Erlinge D, Gurbel PA, James S, Lindahl TL, Svensson P, Ten Berg JM, Foley DP, Wagner H, Brown PB, Luo J, Zhou C, Moser BA, Jakubowski JA, Small DS, Winters KJ, Angiolillo DJ. Erlinge D, et al. Among authors: brown pb. J Am Coll Cardiol. 2013 Aug 13;62(7):577-83. doi: 10.1016/j.jacc.2013.05.023. Epub 2013 Jun 7. J Am Coll Cardiol. 2013. PMID: 23747759 Free article. Clinical Trial.
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA, Bergmeijer TO, Tantry US, ten Berg JM, Angiolillo DJ, James S, Lindahl TL, Svensson P, Jakubowski JA, Brown PB, Duvvuru S, Sundseth S, Walker JR, Small D, Moser BA, Winters KJ, Erlinge D. Gurbel PA, et al. Among authors: brown pb. Thromb Haemost. 2014 Sep 2;112(3):589-97. doi: 10.1160/TH13-10-0891. Epub 2014 Jul 10. Thromb Haemost. 2014. PMID: 25008027 Free article. Clinical Trial.
Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Hoppe CC, Styles L, Heath LE, Zhou C, Jakubowski JA, Winters KJ, Brown PB, Rees DC, Heeney MM. Hoppe CC, et al. Pediatr Blood Cancer. 2016 Feb;63(2):299-305. doi: 10.1002/pbc.25771. Epub 2015 Sep 24. Pediatr Blood Cancer. 2016. PMID: 26402148 Clinical Trial.
6,917 results